Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD 

 

 

November 1, 2012 - (ACT) - "Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD)."  Read Full Article

 

Posted on 13-Nov-12 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: